Research on the Pathogenesis of Fungal Infections

A special issue of Antibiotics (ISSN 2079-6382).

Deadline for manuscript submissions: 30 November 2024 | Viewed by 2205

Special Issue Editor


E-Mail Website
Guest Editor
CNRS-UMR 8576, Inserm U1285, University Lille, Lille, France
Interests: Candida species; multidrug-resistant fungi; anti-fungal drugs; modulation of the immune response; intestinal inflammation; gut microbiota; anti-yeast glycan antibodies; fungal cell wall; intravenous immunoglobulin (IVIg); TLRs
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The first volume of the Special Issue “Research on the Pathogenesis of Candida albicans and Other Candida Species” was published in 2022. It was a successful Issue with five published papers and has encouraged us to open a second volume with the same topic.

As a continuation of the Special Issue published in 2022, this second volume aims to update the current knowledge of the pathogenesis of Aspergillus and Candida species in patients with fungal infection and the rise of new multidrug-resistant fungi, the fungal cell wall, and new antifungal drugs. Topics may include but are not limited to:

  • Aspergillosis
  • Mold
  • Aspergillus fumigatus
  • Fungal skin infection
  • Malassezia
  • dermatitis
  • Candida albicans
  • Candida glabrata
  • Candida auris
  • Candida species
  • multidrug-resistant fungi
  • anti-fungal drugs
  • candidiasis
  • immune response
  • intestinal inflammation, gut microbiota
  • anti-yeast glycan antibodies
  • fungal cell wall
  • chitin
  • β-glucans
  • mannans

Dr. Samir Jawhara
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 4053 KiB  
Article
Antifungal Properties of Hydrazine-Based Compounds against Candida albicans
by Louis Camaioni, Dylan Lambert, Boualem Sendid, Muriel Billamboz and Samir Jawhara
Antibiotics 2023, 12(6), 1043; https://doi.org/10.3390/antibiotics12061043 - 12 Jun 2023
Cited by 1 | Viewed by 1904
Abstract
Candida albicans, an opportunistic yeast, is the most common cause of fungal infection. In the past decade, there has been an increase in C. albicans resistance to existing antifungal drugs, which has necessitated the development of new antifungal agents. In the present [...] Read more.
Candida albicans, an opportunistic yeast, is the most common cause of fungal infection. In the past decade, there has been an increase in C. albicans resistance to existing antifungal drugs, which has necessitated the development of new antifungal agents. In the present study, screening 60 compounds from the JUNIA chemical library enabled us to explore an additional 11 hybrid compounds that contain pyrrolidinone rings and hydrazine moieties for their potential antifungal activities. This chemical series was identified with fair to excellent antifungal activities. Among this series, three molecules (Hyd.H, Hyd.OCH3, and Hyd.Cl) significantly reduced C. albicans viability, with rapid fungicidal activity. In addition, these three compounds exhibited significant antifungal activity against clinically isolated fluconazole- or caspofungin-resistant C. albicans strains. Hyd.H, Hyd.OCH3, and Hyd.Cl did not show any cytotoxicity against human cancer cell lines up to a concentration of 50 µg/mL and decreased Candida biofilm formation, with a significant reduction of 60% biofilm formation with Hyd.OCH3. In an infection model of Caenorhabditis elegans with C. albicans, hydrazine-based compounds significantly reduced nematode mortality. Overall, fungicidal activity was observed for Hyd.H, Hyd.OCH3, and Hyd.Cl against C. albicans, and these compounds protected C. elegans from C. albicans infection. Full article
(This article belongs to the Special Issue Research on the Pathogenesis of Fungal Infections)
Show Figures

Figure 1

Back to TopTop